VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Patel Discusses the Cancer Drug Coverage Parity Act

Kavita Patel, MD, MS
Published: Monday, Apr 03, 2017



Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.

The Cancer Drug Coverage Parity Act requires health plans to provide anticancer medications without changing or replacing benefits to increase out-of-pocket costs, reclassifying benefits to increase costs, or applying more restrictive limitations to oral medications—patient administered—than to intravenous or injected medications—physician administered—as per the bill presented to Congress by Leonard Lance on June 11, 2015.

As with a lot of legislation, this act will most likely never reach the President’s desk, says Patel. However, it is still important, she adds, because it sends a signal throughout Washington, DC that says that the conversation around cancer drugs is continuous, and the needs of patients with cancer are a different, specific issue within healthcare.
 


Kavita Patel, MD, MS, policy analyst, Brookings Institution, discusses the Cancer Drug Coverage Parity Act.

The Cancer Drug Coverage Parity Act requires health plans to provide anticancer medications without changing or replacing benefits to increase out-of-pocket costs, reclassifying benefits to increase costs, or applying more restrictive limitations to oral medications—patient administered—than to intravenous or injected medications—physician administered—as per the bill presented to Congress by Leonard Lance on June 11, 2015.

As with a lot of legislation, this act will most likely never reach the President’s desk, says Patel. However, it is still important, she adds, because it sends a signal throughout Washington, DC that says that the conversation around cancer drugs is continuous, and the needs of patients with cancer are a different, specific issue within healthcare.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x